2647
document
Bronchodilatory responses to formoterol , ipratropium , and their combination in patients with stable COPD . We studied 27 patients with stable chronic obstuctive pulmonary disease ( COPD ) in a randomised , single-blind , within-patient , placebo-controlled clinical study . Each patient was assigned on six separate days to receive one of the following drug regimens in random order : A . 40 micrograms ipratropium bromide ( Atrovent MDI , 20 micrograms/puff ) plus 2 puffs placebo ; B . 12 micrograms formoterol fumarate ( Foradil MDI , 12 micrograms/puff ) plus 3 puffs placebo ; C. 80 micrograms ipratropium ; D. 24 micrograms formoterol plus 2 puffs placebo ; E. 12 micrograms formoterol plus 40 micrograms ipratropium plus 1 puff placebo ; F. 4 puffs placebo . On each study day , spirometric indices and vital signs were measured at 5 , 10 , 15 and 60 minutes , and hourly thereafter up to and including 12 hours after study drug administration . Mean peak FEV1 change ( primary endpoint ) was maximum with the administration of the combination of ipratropium and formoterol ( 335.2 ml , SE 24.6 ) , and it differed significantly from the observed peak changes following single administration of the two tested doses of ipratropium ( p < 0.05 and p < 0.05 respectively ) . Safety and tolerability were satisfactory throughout the study .
2648
Intervention_Pharmacological
formoterol
2649
Intervention_Pharmacological
ipratropium
2650
Intervention_Pharmacological
combination
2651
Intervention_Control
placebo-controlled
2652
Intervention_Pharmacological
ipratropium bromide ( Atrovent MDI , 20 micrograms/puff )
2653
Intervention_Control
2 puffs placebo
2654
Intervention_Pharmacological
formoterol fumarate ( Foradil MDI , 12 micrograms/puff )
2655
Intervention_Control
3 puffs placebo
2656
Intervention_Pharmacological
80 micrograms ipratropium
2657
Intervention_Pharmacological
24 micrograms formoterol plus 2 puffs placebo
2658
Intervention_Pharmacological
12 micrograms formoterol
2659
Intervention_Pharmacological
40 micrograms ipratropium
2660
Intervention_Control
1 puff placebo
2661
Intervention_Control
4 puffs placebo
2662
Intervention_Pharmacological
ipratropium
2663
Intervention_Pharmacological
formoterol
2664
Intervention_Pharmacological
ipratropium
2665
Outcome_Physical
Bronchodilatory responses
2666
Outcome_Physical
spirometric indices and vital signs
2667
Outcome_Physical
Mean peak FEV1 change
2668
Outcome_Other
Safety and tolerability
2669
Participant_Condition
patients with stable COPD .